Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 24
Treatment-assignment count: 0
Stratification count: 0
NSCLC · Monoclonal Antibody
EGFR L858R is flagged as trial selection rising because public trials show inclusion required evidence in 25 contexts. FDA CDx context should be reviewed manually.
Strongest role: Inclusion Required
Inclusion-required count: 24
Treatment-assignment count: 0
Stratification count: 0
Threshold count: 9
Common snippets: MET exon 14 skipping | BRAF V600E | EGFR Exon 19 deletion
Threshold label: Moderate
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT02648724 | https://clinicaltrials.gov/study/NCT07272642 | https://clinicaltrials.gov/study/NCT04746924 | https://clinicaltrials.gov/study/NCT04310007 | https://clinicaltrials.gov/study/NCT07416058 | https://clinicaltrials.gov/study/NCT03846310 | https://clinicaltrials.gov/study/NCT04591431 | https://clinicaltrials.gov/study/NCT03049618 | https://clinicaltrials.gov/study/NCT02367781 | https://clinicaltrials.gov/study/NCT04790409 | https://clinicaltrials.gov/study/NCT07674368 | https://clinicaltrials.gov/study/NCT07259226 | https://clinicaltrials.gov/study/NCT07393555 | https://clinicaltrials.gov/study/NCT04841538 | https://clinicaltrials.gov/study/NCT03958097 | https://clinicaltrials.gov/study/NCT05800015 | https://clinicaltrials.gov/study/NCT07082179 | https://clinicaltrials.gov/study/NCT05756972 | https://clinicaltrials.gov/study/NCT04033354 | https://clinicaltrials.gov/study/NCT04507217 | https://clinicaltrials.gov/study/NCT06868836 | https://clinicaltrials.gov/study/NCT03952403 | https://clinicaltrials.gov/study/NCT03594747 | https://clinicaltrials.gov/study/NCT04244552 | https://clinicaltrials.gov/study/NCT04300556